Does Rallies show Form 4 insider transactions for CAPR?

Yes. Rallies tracks CAPR insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is CAPR research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CAPR. It does not provide personalized investment advice.

CAPR (Capricor Therapeutics Inc) Stock Analysis - Insider Trades

Capricor Therapeutics Inc (CAPR) is a publicly traded Healthcare sector company. As of May 21, 2026, CAPR trades at $30.24 with a market cap of $1.62B and a P/E ratio of -24.46. CAPR moved +7.82% today. Year to date, CAPR is +16.93%; over the trailing twelve months it is +163.49%. Its 52-week range spans $4.30 to $40.37. Analyst consensus is strong buy with an average price target of $54.50. Rallies surfaces CAPR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading CAPR stock inside the company?

Recent CAPR insider activity includes Krasney Karen sold 25.00K, Bergmann Anthony sold 25.00K, Sabar Karimah Es sold 7.53K, Sabar Karimah Es sold 53.73K, and Krasney Karen sold 25.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

CAPR Key Metrics

Key financial metrics for CAPR
Metric	Value
Price	$30.24
Market Cap	$1.62B
P/E Ratio	-24.46
EPS	$-1.15
Dividend Yield	0.00%
52-Week High	$40.37
52-Week Low	$4.30
Volume	12
Avg Volume	0
Revenue (TTM)	$22.27M
Net Income	$-40.47M
Gross Margin	0.00%

Recent CAPR Insider Trades

Krasney Karen sold 25.00K (~$792.55K) on May 1, 2026.
Bergmann Anthony sold 25.00K (~$792.54K) on May 1, 2026.
Sabar Karimah Es sold 7.53K (~$240.93K) on Apr 2, 2026.
Sabar Karimah Es sold 53.73K (~$1.67M) on Apr 1, 2026.
Krasney Karen sold 25.00K (~$752.93K) on Mar 31, 2026.

Latest CAPR News

Capricor Therapeutics Eyes 27.47% Upside and FDA Decision by August 22 — May 15, 2026
Capricor’s Deramiocel BLA Under FDA Review Ahead of August 22 PDUFA Date — May 12, 2026
Capricor to Release Q1 Results May 12, After Securing US-Japan Deramiocel Deal — May 4, 2026
Capricor Shows Statistically Meaningful Upper-Limb Gains in Phase 3 DMD Trial — Apr 22, 2026
Capricor’s Deramiocel BLA Under FDA Review with August 2026 PDUFA Date, Hits PUL v2.0 and LVEF Endpoints — Mar 12, 2026

CAPR Analyst Consensus

8 analysts cover CAPR: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $54.50.

Common questions about CAPR

Who is trading CAPR stock inside the company?: Recent CAPR insider activity includes Krasney Karen sold 25.00K, Bergmann Anthony sold 25.00K, Sabar Karimah Es sold 7.53K, Sabar Karimah Es sold 53.73K, and Krasney Karen sold 25.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for CAPR?: Yes. Rallies tracks CAPR insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is CAPR research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CAPR. It does not provide personalized investment advice.